非心脏手术中积极保温与常规保温比较(PROTECT):多中心平行组优效性试验
PROTECT研究为多中心平行组优效性试验,纳入中国12个中心及美国Cleveland Clinic共5056例≥45岁、至少一项心血管危险因素、拟行全身麻醉非心脏手术(预计2-6小时)的患者,随机1:1接受积极保温(目标核心体温37°C)或常规保温(目标35.5°C)。主要终点为30天内非心脏手术后心肌损伤、非致命性心脏骤停和全因死亡的复合终点。积极保温组平均最终术中核心体温37.1°C(SD 0.3),常规组35.6°C(SD 0.3)。主要终点在积极保温组2497例中发生246例(9.9%),常规组2490例中发生239例(9.6%),相对风险1.04(95%CI 0.87-1.24,p=0.69),无显著差异。作者认为,在极轻度低体温至完全正常体温至少1.5°C范围内,无证据表明任何实质性结局有变化;手术患者维持核心体温至少35.5°C似乎已足够。
要点
- 非心脏手术患者术中核心体温维持至少35.5°C与积极保温至37°C相比,30天主要心血管复合结局无显著差异(9.9% vs 9.6%,RR 1.04,95%CI 0.87-1.24,p=0.69)。
- 积极保温组平均最终术中核心体温37.1°C(SD 0.3),常规保温组35.6°C(SD 0.3),组间温差约1.5°C。
- 积极保温组不良事件39例(其中严重17例),常规保温组54例(其中严重30例);积极保温组1例严重不良事件被认为可能与保温管理相关。
- 作者认为,在极轻度低体温至完全正常体温至少1.5°C范围内,无证据表明任何实质性结局有变化;维持核心体温至少35.5°C似乎已足够。
适用人群与场景
- 年龄≥45岁、至少一项心血管危险因素、拟行全身麻醉非心脏手术且预计手术时长2-6小时、预计至少一半前胸皮肤表面可用于保温的住院患者。
- 排除需透析患者及体重指数超过30 kg/m²的患者。
处置流程与药物剂量
- 积极保温组:术中目标核心体温37°C。
- 常规保温组:术中目标核心体温35.5°C。
研究设计与关键结果
- 研究类型:多中心、平行组、优效性试验;中国12个中心及美国Cleveland Clinic参与;纳入5056例,意向性治疗人群5013例(积极保温组2507例,常规保温组2506例)。
- 干预与对照:积极保温(目标核心体温37°C) vs 常规保温(目标核心体温35.5°C)。
- 主要终点(30天内非心脏手术后心肌损伤、非致命性心脏骤停、全因死亡复合终点):积极保温组2497例中246例(9.9%) vs 常规保温组2490例中239例(9.6%),相对风险1.04(95%CI 0.87-1.24,p=0.69)。
- 不良事件:积极保温组39例(严重17例),常规保温组54例(严重30例);积极保温组1例严重不良事件被认为可能与保温管理相关。
证据类型、等级与局限
- 证据类型:多中心、平行组、优效性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在极轻度低体温至完全正常体温至少1.5°C范围内,无证据表明任何实质性结局有变化;手术患者维持核心体温至少35.5°C似乎已足够。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Moderate intraoperative hypothermia promotes myocardial injury, surgical site infections, and blood loss. Whether aggressive warming to a truly normothermic temperature near 37°C improves outcomes remains unknown. We aimed to test the hypothesis that aggressive intraoperative warming reduces major perioperative complications.
METHODS: In this multicentre, parallel group, superiority trial, patients at 12 sites in China and at the Cleveland Clinic in the USA were randomly assigned (1:1) to receive either aggressive warming to a target core temperature of 37°C (aggressively warmed group) or routine thermal management to a target of 35·5°C (routine thermal management group) during non-cardiac surgery. Randomisation was stratified by site, with computer-generated, randomly sized blocks. Eligible patients (aged ≥45 years) had at least one cardiovascular risk factor, were scheduled for inpatient non-cardiac surgery expected to last 2-6 h with general anaesthesia, and were expected to have at least half of the anterior skin surface available for warming. Patients requiring dialysis and those with a body-mass index exceeding 30 kg/m2 were excluded. The primary outcome was a composite of myocardial injury (troponin elevation, apparently of ischaemic origin), non-fatal cardiac arrest, and all-cause mortality within 30 days of surgery, as assessed in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03111875.
FINDINGS: Between March 27, 2017, and March 16, 2021, 5056 participants were enrolled, of whom 5013 were included in the intention-to-treat population (2507 in the aggressively warmed group and 2506 in the routine thermal management group). Patients assigned to aggressive warming had a mean final intraoperative core temperature of 37·1°C (SD 0·3) whereas the routine thermal management group averaged 35·6°C (SD 0·3). At least one of the primary outcome components (myocardial injury after non-cardiac surgery, cardiac arrest, or mortality) occurred in 246 (9·9%) of 2497 patients in the aggressively warmed group and in 239 (9·6%) of 2490 patients in the routine thermal management group. The common effect relative risk of aggressive versus routine thermal management was an estimated 1·04 (95% CI 0·87-1·24, p=0·69). There were 39 adverse events in patients assigned to aggressive warming (17 of which were serious) and 54 in those assigned to routine thermal management (30 of which were serious). One serious adverse event, in an aggressively warmed patient, was deemed to be possibly related to thermal management.
INTERPRETATION: The incidence of a 30-day composite of major cardiovascular outcomes did not differ significantly in patients randomised to 35·5°C and to 37°C. At least over a 1·5°C range from very mild hypothermia to full normothermia, there was no evidence that any substantive outcome varied. Keeping core temperature at least 35·5°C in surgical patients appears sufficient.
FUNDING: 3M and the Health and Medical Research Fund, Food and Health Bureau, Hong Kong.
TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
参考来源
- Sessler DI, Pei L, Li K, et al. Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial. Lancet. 2022. PMID: 35390321. doi:10.1016/S0140-6736(22)00560-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。